COMMUNIQUÉS West-GlobeNewswire

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment
23/12/2025
Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve- [...]
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
23/12/2025
Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason Lickliter will present a [...]
Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
23/12/2025
- Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition consideration DUBLIN [...]
Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
23/12/2025
Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) [...]
HealthLynked Announces Strategic Consulting Partnership With PBACO to Accelerate Payer Integration and Value-Based Care
23/12/2025
NAPLES, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a leading provider of AI-enabled patient-care coordination and healthcare interoperability solutions, today announced a [...]
MAPS Supports Therapy Education for First-Ever Department of Defense-Affiliated MDMA-Assisted Therapy Pilot
23/12/2025
Training supports multi-site clinical trial of MDMA-assisted Massed Prolonged Exposure Therapy for PTSD in active-duty service members. First-of-its-kind therapist preparation supports the Department of Defense-funded [...]
Kailera Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
23/12/2025
WALTHAM, Mass. and SAN DIEGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron [...]
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
23/12/2025
SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to [...]
Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.
23/12/2025
PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Merit Medical to Participate at the J.P. Morgan Healthcare Conference
23/12/2025
SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan [...]
J-Star’s LITZMO Introduces ER-01: The Brand’s First Carbon Fiber Fat-Tire E‑Assist Bicycle
23/12/2025
TAICHUNG CITY, Taiwan, Dec. 23, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions serving diverse [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
23/12/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 23 December 2025 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Communiqué de presse : Wayrilz de Sanofi approuvé dans l’UE comme premier inhibiteur de la BTK pour le traitement de la thrombocytopénie immunitaire (TPI)
23/12/2025
Wayrilz de Sanofi approuvé dans l’UE comme premier inhibiteur de la BTK pour le traitement de la thrombocytopénie immunitaire (TPI) Un traitement novateur cible la BTK grâce à la modulation multi-immune pour aider à [...]
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
23/12/2025
Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Approval based on [...]
Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure
23/12/2025
CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today [...]
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
23/12/2025
BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the [...]
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
23/12/2025
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Top- [...]
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
23/12/2025
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by [...]
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
23/12/2025
Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory Disease CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company [...]

Pages